Are Teva's Best Days Behind It?

After losing a patent challenge in U.S. District Court, it's become increasingly likely that Teva Pharmaceutical Industries' (NYSE:TEVA) top-selling Copaxone will face generic competition soon. Since Copaxone accounts for 16% of Teva Pharmaceutical's sales, and over 40% of its operating profit, investors are right to be nervous. Can Teva Pharmaceutical side-step the risk to Copaxone and reward investors?